Cipla To Market Roche’s Drug Cocktail To Treat Covid-19 In India
Roche Holding AG has received restricted emergency use approval from the Indian drug regulator for a product used to treat Covid-19 infections.
This will enable Roche Pharma India to import the product—a cocktail of the antibodies casirivimab and imdevimab—in India, Cipla Ltd. said in an exchange filing, adding it will market and distribute it in the country.
Approval was granted based on data that have been filed for emergency use in the U.S., and the scientific opinion of the Committee for Medicinal Products for Human Use in the European Union, Cipla said.
The product will be used to treat mild to moderate Covid-19 in adults and paediatric patients (12 years of age or older, weighing at least 40 kg) who are confirmed to be infected with SARS-COV2 and are at high risk.
“Neutralising antibody cocktails like casirivimab and imdevimab can play a role in the fight against Covid-19 and in treatment of high-risk patients before their condition worsens,” V Simpson Emmanuel, managing director of Roche Pharma India, was quoted as saying. The drug will be available through leading hospitals and Covid-19 treatment centres in India.
In March, Roche said a large phase III global trial in high-risk non-hospitalised Covid-19 patients met its primary endpoint, which showed casirivimab and imdevimab significantly reduced risk of hospitalisation or death by 70% compared to placebo. The antibody cocktail also significantly shortened the duration of symptoms by four days, Cipla said.
Last month Cadila Healthcare Ltd. received restricted emergency use approval from the Indian drug regulator for its pegylated interferon alpha-2b, or virafin, for treating moderate Covid-19 infection in adults.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.